 |
|
|
|
July 2006 Cover
|
|
Patients who initiate antiretroviral treatment with a regimen containing lopinavir/ritonavir (Kaletra) are at a greater risk for developing elevated blood pressure, according to the results of a 444-patient U.S. study
published in AIDS. The Washington University HIV Cohort study found a 2.5-fold greater risk of elevated blood pressure in patients who initiated treatment with lopinavir/ritonavir compared to efavirenz (Sustiva, Stocrin).
By contrast, patients initiating therapy with atazanavir (Reyataz) appeared to be most protected from elevated blood pressure, with a risk approximately 80% lower than patients initiating therapy with
lopinavir/ritonavir. The researchers noted that the increased blood pressure among lopinavir/ritonavir patients appeared to be mediated by a rise in body mass index after treatment initiation
Editor's Note: from thebodypro.com
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
